Phase 2 N=10 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
Obesity · Overweight · Craniopharyngioma
Primary: Body Weight (kg) — -1.4 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 MRI for Non-invasive Evaluation of Brain Stress
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
N/A N=30 Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
Glioblastoma Multiforme
Primary: Number of Participants With Local Recurrence in the Spared NPC Niches — 0 Participants
N/A N=43 Peri-Operative Steroid Management in Patients
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
N/A N=162 Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants
Phase 2 N=100 Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Phase 2 N=25 PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
Brain Tumor
Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants
N/A N=54 Proton Radiation for Chordomas and Chondrosarcomas
Chordomas · Chondrosarcomas
Primary: Feasibility of Proton RT for Chordomas and Chondrosarcomas — 3.7; 1.9 percentage of patients did not meet this
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Phase 2 N=202 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
Central Nervous System Tumors · Brain Tumors
Primary: Local Tumor Control — 0.966; 0.959; 1.000; 1.000 Proportion of patients
Phase 2 N=34 Monthly SOM230C for Recurrent or Progressive Meningioma
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Phase 2 N=9 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Neurofibromatosis 2 · Progressive Vestibular Schwannoma (VS)
Primary: Volumetric Response Rate — 0; 9 Participants
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Phase 2 N=3 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Paranasal Sinus Cancer · Nasal Cavity Tumor · Nasal Cavity Adenocarcinoma
Primary: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
N/A N=90 Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Brain Tumor · Medulloblastoma · Pineoblastoma
Primary: Cumulative Incidence of Ototoxicity — 26; 27 percentage of participants
Phase 2 N=32 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Phase 2 N=8 Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
Metastatic Medulloblastoma · High Risk Supratentorial PNET · Metastatic PNET
Primary: Event-free Survival — 7 Participants
Phase 2 N=9 Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Juvenile Pilocytic Astrocytomas · Optic Pathway Gliomas
Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants
Phase 2 N=7 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
Phase 4 N=41 Surgical Debulking of Pituitary Adenomas
Pituitary Adenoma
Primary: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2) — 6.7; 50 percentage of participants
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
N/A N=59 Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma
Brain and Central Nervous System Tumors · Long-term Effects Secondary to Cancer Therapy in Children
Primary: Cumulative Incidence of Ototoxicity — 12; 16; 16; 15 percentage of participants
Phase 4 N=62 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Pituitary Tumor · Pain
Primary: Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour) — 1.7; 2.8 0-10 units on a scale
N/A N=12 PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Phase 1 N=3 Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 3 N=165 Idiopathic Intracranial Hypertension Treatment Trial
Idiopathic Intracranial Hypertension
Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05
Phase 2 N=47 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Phase 2 N=18 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas